相关实验视频

Updated: Jun 8, 2025

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.2K

β-粉样蛋白损害蛋白质体的结构和功能. 蛋白质酶激活减轻了粉样蛋白诱导的毒性和认知缺陷

Kanisa Davidson, Mehar Bano, Danitra Parker

    bioRxiv : the preprint server for biology
    |November 1, 2024
    PubMed
    概括

    阿尔茨海默病 (AD) 涉及由于β-粉样蛋白 (Aβ) 积累而导致蛋白酶体功能受损. 蛋白酶激活剂TAT1-8,9TOD和TAT1-DEN在细胞和动物模型中显示出恢复功能和减轻AD类缺陷的希望.

    更多相关视频

    A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis06:17

    A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

    Published on: May 22, 2018

    11.8K
    Imaging the Intracellular Trafficking of APP with Photoactivatable GFP07:55

    Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

    Published on: October 17, 2015

    11.8K

    相关概念视频

    Amyloid Fibrils03:03

    Amyloid Fibrils

    Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
    Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
    9.3K
    The Proteasome01:13

    The Proteasome

    Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
    In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
    815
    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
    449
    The Proteasome Structure01:17

    The Proteasome Structure

    The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
    The proteasome is an...
    708
    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    165